Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trumenba in Immunocompromised Participants
NCT04893811Phase 4Completed
- Sponsor
- Pfizer
- Start
- Aug 2021
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of meningococcal group B vaccine in Meningococcal Disease Group B, sponsored by Pfizer. Primary endpoints: Serum Bactericidal Assay Using Human Complement Titer at Month 7, Local Reactions and 8 more. Started Aug 2021; status: completed.
02
Drugs
meningococcal group B vaccine
03
Conditions
Meningococcal Disease Group B
Beyond the preview
Go deeper on NCT04893811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04893811.